BDBM178186 US9120808, Example 5::US9120808, Example 6

SMILES O=CC=C1O[C@@H]2CC(=O)N2C1(CC=Cc1ccccc1)C(=O)OCc1ccccc1

InChI Key InChIKey=KBUJSCWFZMYQLR-UHFFFAOYSA-N

Data  6 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 6 hits for monomerid = 178186   

TargetBeta-lactamase(Escherichia coli (strain K12))
Nabriva Therapeutics

US Patent
LigandPNGBDBM178186(US9120808, Example 6 | US9120808, Example 5)
Affinity DataIC50: 5.82E+3nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178186(US9120808, Example 6 | US9120808, Example 5)
Affinity DataIC50: 7.14E+3nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178186(US9120808, Example 6 | US9120808, Example 5)
Affinity DataIC50: 4.92E+3nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase(Escherichia coli (strain K12))
Nabriva Therapeutics

US Patent
LigandPNGBDBM178186(US9120808, Example 6 | US9120808, Example 5)
Affinity DataIC50: 1.71E+4nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178186(US9120808, Example 6 | US9120808, Example 5)
Affinity DataIC50: 3.95E+3nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178186(US9120808, Example 6 | US9120808, Example 5)
Affinity DataIC50: 2.79E+3nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent